Background. Community-onset Clostridium difficile infections (CDI) are increasingly common, but there is little data on outcomes. The purpose of this study is to describe the epidemiology and outcomes of CDI in the Veterans Health Administration (VHA) system and compare these variables between hospital-onset (HCF) and community-onset (CO) cases.
Demographic data (age, sex, race/ethnicity, region of facility) and medical diagnoses (comorbidities noted in the last 365 days prior to CDI) were obtained from the VA inpatient, outpatient, Spatient, and vital signs domains and were subsequently linked to related dimension tables in CDW. Mortality data was obtained from Spatient and vital status using a 2-step algorithm to improve the capture of events. Comorbidities included in the Deyo-Charlson comorbidity index were identified by International Classification of Diseases, Ninth Revision (ICD-9) codes, as described in previous studies [6, 7] . Antibiotics and other drugs were identified by VA drug class from outpatient records and bar code medication administration using local and national data sources. Medication history was obtained from pharmacy outpatient and pharmacy bar code medication management domains. Laboratory test results were extracted from the lab chemistry domain, linked to related-dimension tables in CDW.
Case Definition

Inclusion Criteria
CDI cases were identified by the presence of a positive test for C. difficile within CDW between 2011-2014. A positive test was defined by either a positive microbiologic culture or positive toxin determined by toxin enzyme immunoassay (EIA) or a positive toxin gene determined by polymerase chain reaction; patients with a glutamate dehydrogenase (GDH) test were included only if the GDH was accompanied by a positive toxin by EIA or a positive toxin gene by polymerase chain reaction within 1-2 days. Classifications of CDI cases, settings, and mode of acquisition were undertaken as in CDI surveillance recommendations [8] :
1. HCF cases were defined as those with a positive test at least 48 hours after admission to a VA hospital. 2. CO cases were defined as those with a positive test occurring in the outpatient setting or within 48 hours of admission to a VA hospital, provided the patient had not been discharged from a hospital in the previous 12 weeks.
• Community-onset, hospital-onset-associated (CO-HCFA) cases were defined as those with a positive test in the outpatient setting or within 48 hours of admission to a VA hospital when the patient had been discharged from a hostpital within the previous 4 weeks.
• Community-associated, indeterminate cases (CA- IND) were defined as those with a positive test in the outpatient setting or within 48 hours of admission to a VA hospital when the patient had been discharged from a hospital within the previous 4-12 weeks [8] .
Duplicate cases were defined as those in which the number of days from a previous positive CDI event to the current positive test result was 14 days or less. Recurrent cases were defined as those in which the number of days from a previous positive CDI event to the current positive test result was >14 and ≤56 days (2-8 weeks). A positive result more than 8 weeks after the last positive result was classified as a new case [8] . Duplicate and recurrent cases were excluded from the analysis. Severity of CDI was defined according to the guidelines published in 2018 by the Society for Healthcare Epidemiology of America (SHEA) and Infectious Disease Society of America (IDSA) [9, 10] . In this classification, cases are categorized as non-severe, severe, or fulminant [9] . Non-severe cases are those with a white blood cell count <15 000 cells/μL and serum creatinine less than 1.5mg/dL and severe cases are those with a white blood cell count ≥15 000 cells/μL or serum creatinine equal or greater than 1.5mg/dL. The peak value for white blood cell count and serum creatinine within 72 hours of the positive CDI test were chosen to define severity. Finally, fulminant cases included those with hypotension or shock (ICD9 code: 785.5), ileus (ICD9 code: 560.1), or megacolon (ICD code: 564.7), and those that underwent colon resection in the 2 days after CDI diagnosis. If data were not available, the severity was classified as indeterminate.
The outcomes measured included: recurrence, 30-day allcause mortality, and-for those with an inpatient stay-length of stay after CDI diagnosis and disposition.
Validation of Results
Setting onset was validated (by M. C. M. P.) through a chart review of 30% of the cases diagnosed at the William S. Middleton Memorial Veterans Hospital during the study period. The agreement criteria between the algorithm-generated category and the manual categorization were as follows: setting onset had a weighted kappa of 0.88 (95% confidence interval [CI] 0.62-0.92).
Statistical Analysis
Bivariate statistics were used to compare demographic and clinical characteristics by epidemologic onset of CDI using chisquare tests. The normality of continuous variables was analyzed using Kolmogorov-Smirnov statics and the differences of continuous variables according to categorical variables were assessed using Kruskal-Wallis (non-parametric) or analyses of variance for those normally distributed. A 2-sided P-value of ≤0.05 was considered statistically significant.
Unadjusted Kaplan-Meier survival curves with 95% confidence bands (Hall-Wellner bands) were used to characterize 30-day all-cause mortality. Factors associated with 30-day all-cause mortality at the P ≤ 0.1 level in bivariate analyses were included in a Cox proportional hazard model that used a robust, sandwich covariance matrix estimate according to the technique described by Lee, Wei, Amato, and Leurgans [11] and that considered correlated data from repeated events by clustering using the variable of patient identification.
A multivariable logistic regression model, using the GENMOD procedure with the REPEATED statement to account for correlated data that arose from repeated events, was used to characterize the factors associated with having a fulminant case; the clustering variable was patient identification and the correlation matrix was independent.
Patients with missing data were included in the analysis using indicator variables representing missing data. Analyses were conducted using SAS 9.4 (SAS Institute, Inc. Cary, NC) within the VA Informatics and Computing Infrastructure. Abbreviations: CA-IND, community-associated, indeterminate cases; CDI, Clostridium difficile infection; CHF, congestive heart failure; COPD: chronic obstructive pulmonary disease; CO, community-onset; CO-HCFA, community-onset, hospital-onset-associated; CVD, cardiovascular disease; HCF, hospital-onset; PVD, peripheral vascular disease; SD, standard deviation. a Percentages by severity level equal 100% within each column.
There were 2 797 700 inpatient admissions and 342 million outpatient visits to the VHA between 2011 and 2014 [12] . During the same period, we identified 19 270 episodes of CDI that involved 15 972 unique patients; 95.1% of which were male and the mean age at initial CDI diagnosis was 68.7 years. We determined that 44% of cases were HCF (mean age 69.3 years), 42% were CO (mean age 67.5 years), 9% were CO-HCFA (mean age was 70.5 years), and 5% were CA-IND (mean age 69.9 years; Supplementary Table 1) . There were 0.3 HCF cases per 100 admissions. Severity of the cases was distributed as follows: 30.6% of the cases were non-severe, 40.4% were severe, 21.3% were fulminant, and 7% were indeterminate severity (due to missing laboratory data). Table 1 shows demographic characteristics according to severity. Non-severe cases were more likely to have been HCF (Table 1 ) and had similar medication exposures as compared to fulminant cases; patients with non-severe cases were less likely than those with fulminant cases to have visited a healthcare facility (emergency department, hemodialysis, or chemotherapy) prior to diagnosis (Table 2) .
In multivariable analyses (Table 3) , factors associated with increased odds of fulminant disease were exposure to clindamycin (odds ratio [OR] 1.23, 95% CI 1.06-1.44, P = .01) or proton pump inhibitors (OR 1.20, 95% CI:1.12-1.29; P < .001) in the 90 days prior to diagnosis. The variables associated with decreased odds of fulminant diseases were: African-American race (OR 0.77, 95% CI 0.70-0.85; P < .001), being service connected (50-100%; OR: 0.87, 95% CI 0.80-0.95; P < .001), being exposed to sulfamethoxazole/trimethoprim within 90 days of diagnosis (OR 0.86, 95% CI 0.75-0.99; P = 0.04), and use of lactobacillus in the 90 days prior to diagnosis (OR 0.90, 95% CI 0.82-0.99; P = 0.04).
When compared with non-severe cases, fulminant cases had a longer median length of stay after diagnosis (6 days vs 4 days), higher recurrence rates (16% vs 13.7%), fewer discharges to home (77.7 vs 82.8%), and a higher 30-day all-cause mortality rate (14.8% vs 5.9%; Table 4 ).
The 30-day all-cause mortality after CDI diagnosis was 9.2%. In a multivariable analysis, the factors associated with increased 30-day all-cause mortality were greater age, a higher Charlson score, greater case severity, and exposure to extended-spectrum penicillin 90 days before diagnosis (Table 5 ).
Demographics and Exposures According to Setting of Onset
When demographics were analyzed according to setting of onset, there were different patterns seen in the distribution of patients by age group, gender, Charlson score, comorbidities, and region (Supplementary Table 1 ). Overall, 40% of patients received antibiotics in the 90 days before CDI diagnosis, and the frequency of use varied by setting of CDI onset: 30% use among CA-IND cases, 35.5% among CO cases, 43.9% among HCF cases, and 49.9% among CO-HCFA cases. Clindamycin was used in 5% of all patients, but its use was less likely among HCF cases compared to CO-HCFA cases (4.4% vs 6.0%). Fluoroquinolone use was more likely among those cases with CO-HCFA and HCF (33% vs 27%) than with CO (21%). Lactobacillus probiotics were used in 17% of all cases, but their use was more common among those with HCF (19.2%) compared with CO (15.0%).
Proton pump inhibitors were used in 53% of all cases, with usage most common in HCF cases (62%) and least common in CA-IND cases (31%; Supplementary Table 2) .
Outcomes According to Setting of Onset
Recurrence was noted in 18.2% of all cases, with a lower frequency of recurrence noted among HCF cases (13.8%) compared to CO cases (22%; Supplementary Table 3 ). Discharge to home was noted in 89% of CO, 66% of CO-HCFA, and 76% of HCF cases.
DISCUSSION
To our knowledge, our study is among the few to include patientand case-level data on the epidemiology of CDI in the VHA and to examine clinically-relevant outcomes. Previous studies of CDI within the VHA system [4, 5] have focused largely on HCF CDI [3, 13] or specific subsets of the population [6, 14, 15] . Important findings from our study include confirming certain risk factors for incidents of CDI in the HCF population, such as antibiotic exposure in the preceding 90 days, higher allcause mortality, and comorbid conditions. Our findings show that the proportion of CDI in the VHA system that is HCF (43.7%) versus CO (42%) is consistent with previously-published data collected from other VHA sources [4, 5] . This shift towards higher rates of CO cases compared to historical data has been noted both inside and outside of the VHA system [16] [17] [18] [19] , and our study provides confirmation of the magnitude of the shift within the VHA system. Similar to results outlined in this study, Khanna et al. showed that in a population-based study in Minnesota, CO cases represented 41% of all CDI, and patients with CO CDI were more likely to be younger and healthier, less likely to have a severe infection, and less likely to have been exposed to antibiotics [20] .
Studies in the general population have compared patient characteristics between CO and HCF CDIs and determined that those with CO were more likely to be younger and have milder diseases [21, 22] , but these cases could still lead to hospitalization and might not be associated with classic HCF CDI risk factors [23] . Severity of disease was described according to SHEA/IDSA 2017 guidelines [10] and, to our knowledge, our study is the first to describe severity in a large population using these guidelines. SHEA/IDSA severity classification is based on previous risk factors identified in the literature and its main purpose is to guide treatment selection [24] . Other severity score indices for CDI have been developed [25, 26] ; however, SHEA/IDSA are the most widely used and previous studies have validated their agreement with risk factors and outcomes [27] . Our study highlights the importance of severity in all-cause 30-day mortality, and the burden associated with additional lengths of stay and recurrences of disease. Regarding risk factors for fulminant cases, age has been shown to be associated with severity in several studies [28, 29] . This was not a significant association in our study, but there was a trend to significance in the group aged 65-84. Prior acid suppression has been previously identified as a risk factor for severe cases [30] , which correlates with the results of our study. In our study, exposure to sulfamethoxazole/ trimethoprim or lactobacillus was associated with lower odds of a fulminant disease, which might relate to a selection bias in treatment protocols, where patients with a better health status received these medications more frequently. More research is required to assess the relationship between these factors.
Our findings also show that antibiotic use is associated with both CO and HCF CDI. Clindamycin and fluoroquinolones led to a similar, if not increased, risk for incident CO CDI compared with HCF CDI. These antibiotics have been identified in the past as risk factors for CO CDI [19] . Although the VHA has implemented programs in healthcare settings, such as acute care and long-term care facilities, to curb the increase of HCF CDI [31] , the proportion of CO cases suggests that programs targeting CDI prevention, such as antimicrobial stewardship, should also include outpatient settings. Outpatient antimicrobial stewardship programs have shown promise [32] , but further work is needed to implement these programs broadly. In addition, translating infection control practices known to be effective for the inpatient setting to the outpatient setting is a challenge, but may be a major opportunity to prevent CDI [33] .
Our results show that recurrence of CDI in the VHA system is 18%, which is similar to other studies, where rates have been shown to be between 12% and 64% (median 22%) [6, 18, 19, 28] . In addition, we found that recurrence was more common in the CO groups within the VHA, which has also been noted in non-VHA studies [28] . In addition, it has been shown previously that there are variations in recurrence according to severity, with recurrence being associated with complicated (fulminant) CDI [28] . In our study, exposures were evaluated before the first episode of CDI; therefore, risk factors associated with recurrence, such as concomitant use of antibiotics or proton pump inhibitors, could not be evaluated.
Our study was not able to identify the rates of CDIattributed death, but the 30-day all-cause mortality in our study was 9.2%, which is at the lower end of the range noted in studies of the general population (8-53%, median 19%) [28] , but higher than another study of surgical patients at the VHA who underwent non-cardiac procedures (5.3%) [3] . All-cause mortality was lower in CO CDI, similar to studies in non-VHA settings [1, 28, 34, 35] , possibly due to the lower prevalence or severity of comorbid conditions. Previously-reported risk factors for 30-day mortality are increasing age, comorbidities, and fulminant cases; our study confirms some of these as risk factors for death in the VHA population. Exposure to clindamycin was associated with a lower risk of death at 30 days in our study; this is likely due to residual confounding, as patients that received clindamycin prior to their CDI diagnosis were more likely to be CO cases, be younger, and have a less severe manifestation of CDI.
Limitations of our study include those associated with all retrospective studies. Although we included several laboratory results in our study, we were unable to include clinical information stored in free-text form (symptoms, severity of disease). Our results only include information within the VHA system; therefore, if patients received care in other systems whose information was not included in this study, it might affect the classifications of setting onset and exposure to healthcare facilities (eg, hospital admissions, long-term care stays). To minimize the effect of missing data, we included data from sources of admission and matched it with information from admissions occurring before the CDI diagnosis (eg, disposition, long-term care).
Similarly, there are site-specific differences in testing and administrative coding that could not be assessed, because our validation process included patients seen at a single site. Previous research studies have estimated that the agreement between laboratory results and symptomatic clinical disease is 81%, where the disagreement lies on the overestimation of cases when using only laboratory results [36, 37] .
The absence of a control group prevents us from estimating incidence and risk factors for CDI infection or the overall risk of CDI when exposed to a specific medication or an outpatient healthcare facility (eg, surgery centers, hemodialysis, infusion clinics). Other limitations are the lack of adjustment for multiple comparisons, the absence of cause of death in this cohort, and that the population was predominantly male veterans, limiting the generalizability of results to the general population.
CONCLUSION
CO CDI accounts for a significant proportion of cases in the VHA. This group tends to be younger and healthier than those with HCF CDI, but may be at greater risk for recurrence. Greater severity of CDI is associated with worse outcomes, including higher all-cause mortality. The burden of CDI in the community should lead to interventions for CDI prevention that are focused on the outpatient and community settings.
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